5-membered heterocycle-based p38 kinase inhibitors

Details 5-membered heterocycle-based p38 kinase inhibitors 5-membered heterocycle-based p38 kinase inhibitors

2011-01-04

2011-01-04

Loewe, Sun Jae Y (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S371400

Reexamination Certificate

active

07863314

ABSTRACT:
Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38α and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.

REFERENCES:
patent: 6441018 (2002-08-01), Faraci et al.
patent: 6444696 (2002-09-01), Goldstein et al.
patent: 6448265 (2002-09-01), Faraci et al.
patent: 2002/0016333 (2002-02-01), Faraci et al.
patent: 2002/0049227 (2002-04-01), Faraci et al.
patent: 2002/0103245 (2002-08-01), Goldstein et al.
patent: 2002/0156114 (2002-10-01), Goldstein et al.
patent: 2003/0018051 (2003-01-01), Goldstein et al.
patent: 1152421 (1963-08-01), None
patent: 19518054 (1996-09-01), None
patent: 0 691 128 (1996-01-01), None
patent: 0 713 876 (1996-05-01), None
patent: 0 639 574 (1998-06-01), None
patent: 47031979 (1972-11-01), None
patent: 49101373 (1974-09-01), None
patent: 51112341 (1976-10-01), None
patent: WO 94/13643 (1994-06-01), None
patent: 98/28269 (1998-07-01), None
patent: WO 99/21845 (1999-05-01), None
patent: WO 99/57101 (1999-11-01), None
patent: WO 00/12074 (2000-03-01), None
patent: WO 00/12497 (2000-03-01), None
patent: WO 00/25780 (2000-05-01), None
patent: WO 00/56738 (2000-09-01), None
patent: WO 00/62778 (2000-10-01), None
patent: WO 01/21591 (2001-03-01), None
patent: WO 01/27089 (2001-04-01), None
patent: WO 01/34605 (2001-05-01), None
patent: WO 01/56567 (2001-08-01), None
patent: WO 02/24200 (2002-03-01), None
patent: WO 02/40486 (2002-05-01), None
patent: WO 02/057261 (2002-07-01), None
patent: WO 02/092087 (2002-11-01), None
patent: WO 03/004467 (2003-01-01), None
patent: WO 03/032970 (2003-04-01), None
patent: WO 03/032971 (2003-04-01), None
patent: WO 03/032972 (2003-04-01), None
patent: WO 03/032980 (2003-04-01), None
patent: WO 03/032986 (2003-04-01), None
patent: WO 03/032987 (2003-04-01), None
patent: WO 03/033457 (2003-04-01), None
patent: WO 03/033482 (2003-04-01), None
patent: WO 03/033483 (2003-04-01), None
patent: WO 2004/010995 (2004-02-01), None
patent: WO 2005/063766 (2005-07-01), None
Hacks Chemical Dictionary, Fourth Edition, Julius Grant, 1972, p. 203.
Fact Sheet, Alzheimer's Association 2006 (2 Pages).
http://www.mayoclinic.com/health/alzheimers-disease/DS00161/DSECTION=3 (2 Pages).
Barnes, P.J.; “Mediators of Chronic Obstructive Pulmonary Disease”, Pharmacol. Rev. (2004), vol. 56, p. 515-548.
Kay, A.B.; “Allergy and Allergic Diseases, First of Two Parts”, N. Engl. J. Med. (2001), vol. 344, p. 30-37.
Singh et al. “Differential Expression of Inflammatory Cytokines and Chemokines Genes by Homocystein in the Human Retinal Pigmented Epithelial Cells”, The FASEB Journal (2006), vol. 20, p. A719.
McCulloch et al. “Signalling Platforms that Modulate the Inflammatory Response: New Targets for Drug Development”, Nature Reviews Drug Discovery (2006), vol. 5, p. 864-876.
Al-Afaleq et al., “Heterocyclic synthesis via enaminonitriles: an efficient, one step synthesis of some novel azolo[1,5-a]pyrimidine, pyrimido[1,2-a]benzimidazole, pyrido[1,2-a]benzimidazole, pyrimidine and pyrazole derivatives,” Synthetic Communications 30(11):1985-1999 (2000).
Al-Zaydi et al., “Enaminonitriles in heterocyclic synthesis: New routes for the synthesis of some novel azolo[1,5-a]pyrimidine, pyrimido[1,2-a]benzimidazole, pyrido[1,2-a]benzimidazole, pyrazole[3,4-b]pyridine, pyrazole and pyrimidine derivatives,” Journal of Chemical Research, Synopses (1):13-15, 173-192 (2000).
Koraiem et al., “The sythesis of pyrazolo-and isoxazolo-[3,4-c]-pyrazole hemiazadicarbocyanine dyes,” Journal of Chemical Technology and Biotechnology, Chemical Technology 34A(2):43-50 (1984).
Boehm et al., “New Inhibitors of p38 Kinase,” Expert Opinion on Therapeutic Patents, 10(1):25-37 (2000).
Daidone et al., “Studies on the synthesis of heterocyclic compounds. Part VIII. A facile synthesis of new pyrazolo[3,4-b]benzazepine-4,9-diones”, Journal of Heterocyclic Chemistry (1982) 19(3):689-690.
Rudorf et al., “Reactions of substituted 1-thiochromones and 4(1H˜quinolinones with nucleophiies”, Journal fuer Praktische Chemie (Leipzig) (1981), 323(1):55-62.
Priede, J. et al., “Reaction of 2-cyano-3-ethoxyindenone with hydrazine and some of its derivatives,” Latvijas PSR Zinatnu Akademijas Vestis, Kimijas Serija (1978) 5:579-582.
Rudorf, W.D. et al., “Acylketene-S,S- and acylketene-S,N-acetals as building blocks for heterocycles: pyrazoles and isoxazoles,” Journal fuer Praktische Chemie (Leipzig) (1978) 320(4):585-599.
DeWald et al. “Pyrazolodiazepines. 2. 4-Aryl-1,3-dtalkyl-6,8-dihydropyrazolo[3,4-ej[1,4jdiazepin-7(1H)-ones as antianxiety and anticonvulsant agents,” Journal of Medicinal Chemistry (1977) 20(12):1562-1569.
Nishiwaki et al., “Heterocyclic chemistry. XIX. Synthesis of 4-aroyl-l-arylpyrazoles from a-aroyl-R-anilinoacrylpnitriles and photochemistry of 4-carbonyl substituted pyrazoles”; Journal of the Chemical Society, Perkin Transactions ; Organic and Bio-Organic Chemistry (1972-1999) (1974) 15:1871-1875.
Butler et al., “(1,3-Dialky1-5-amino-1H-pyrazol-4-yl)arylmethanones. A series of novel central nervous system depressants,” Journal of Medicinal Chemistry 27(11):1396-1400 (1984).
Hennig et al., “Synthesis of pyrazolo[3,4-b]quinolines from 4-aroyl-5-chloropyrazoles,” Journal fuer Praktische Chemie (Leipzig) 332(5):693-698 (1990).
Bruns et al., “Structure-activity relationships for enhancement of adenosine A1 receptor binding by 2-amino-3-benzoylthiophenes,” Molecular Pharmacology 38(6):950-958 (1990).
Charris et al., “Synthesis of some thiochrome derivatives and activity against Plasmodium falciparum in-vitro,” Pharmacy and Pharmacology Communications 5(2):107-110 (1999).
Chiba et al., “Substituted 4-Acylpyrazoles and 4-Acylpyrazolones: Synthesis and Multi-drug Resistance-Modulating Activity,” Journal of Medicinal Chemistry 41(21):4001-4011 (1998).
Henry et al., “p38 Mitogen-activated Protein Kinase as a Target for Drug Discovery,” Drugs Fut., 24:1345-1354 (1999).
Salituro et al., “Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases,” Curr. Med. Chem., 6:807-823 (1999).
Rankin et al., “The Terapeutic Effects of an Engineered Human Anti-tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis,” Br. J. Rheumatol., 34:334-342 (1995).
Moreland et al., “Etanercept Therapy in Rheumatoid Arthritis,” Ann. Intern. Med., 130:478-486 (1999).
Han J, Richter B, Li Z, Kravchenko V, Ulevitch RJ. Molecular cloning of human p38 MAP kinase. Biochim Biophys Acta. 1995 ;1265(2-3):224-7.
Jiang Y, Chen C, Li Z, Guo W, Gegner JA, Lin S, Han J. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta).J Biol Chem. Jul. 26, 1996;271(30):17920-6.
Li, Z.; Jiang, Y.; Ulevitch, R. J.; Han, J. : The primary structure of p38-gamma: a new member of p38 group of MAP kinases. Biochem. Biophys. Res. Commun. 228: 334-340, 1996.
Wang, et al., Molecular Cloning and Characterization of a Novel p38 Mitogen-activated Protein Kinase,. J Biol Chem. Sep. 19, 1997;272(38):23668-74.
Nogrady (1985) Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pp. 388-392.
Ceccarelli, S. et al, “Imidazo(1, 2-a)quinoxalin-4-amines: A Novel Class of Nonxanthine AI Adenosine Receptor Antagonists,” European Journal of Medicinal Chemistry vol. 33, (1998), at pp. 943-955.
Murali Dhar, et al., “A Survey of Cyclic Replacements for the Central Diamide Moiety of Inhiboros of Inosine Monophosphate Dehydrog

Affiliated with

Also associated with

Rating

5-membered heterocycle-based p38 kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 5-membered heterocycle-based p38 kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-membered heterocycle-based p38 kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2724025